12/17
04:08 pm
moln
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January [Yahoo! Finance]
Low
Report
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January [Yahoo! Finance]
12/17
04:00 pm
moln
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Low
Report
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
12/8
12:00 pm
moln
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Low
Report
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
11/7
04:00 pm
moln
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Low
Report
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
11/5
04:00 pm
moln
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Medium
Report
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
10/31
04:00 pm
moln
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
High
Report
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
10/25
01:14 am
moln
Molecular Partners Announces Pricing of $20 Million Underwritten Offering [Yahoo! Finance]
Medium
Report
Molecular Partners Announces Pricing of $20 Million Underwritten Offering [Yahoo! Finance]
10/25
01:00 am
moln
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
Medium
Report
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
10/22
01:00 am
moln
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Medium
Report
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
10/22
01:00 am
moln
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Medium
Report
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
10/8
05:52 am
moln
Molecular Partners AG (NASDAQ: MOLN) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Molecular Partners AG (NASDAQ: MOLN) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/4
01:05 am
moln
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting [Yahoo! Finance]
Medium
Report
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting [Yahoo! Finance]
10/4
01:00 am
moln
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Medium
Report
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
9/27
01:07 am
moln
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 [Yahoo! Finance]
Medium
Report
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 [Yahoo! Finance]
9/27
01:00 am
moln
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Medium
Report
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024